• For Individuals
  • For Institutions
  • Download
  • Help

  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
EN
English
简体中文
繁體中文
繁體中文（廣東話）Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials

Event Tracking

Nov12
4D Molecular Therapeutics Receives Buy Rating from H.C. Wainwright Analyst
11:19
Nov11
Morgan Stanley Reiterates Hold Rating on 4D Molecular Therapeutics
12:23
4D Molecular Therapeutics released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 90 K (forecast USD 403 K), actual EPS USD -1.0133 (forecast USD -0.9916)
04:00
4D Molecular Therapeutics released FY2025 9 Months Earnings on November 10, 2025, EST: Actual Revenue USD 119 K, Actual EPS USD -2.8512
04:00
Nov6
4D Molecular Therapeutics Announces Positive Mid-Stage Results for 4D-150 Gene Therapy Drug
11:36
Nov3
4D Molecular Therapeutics and Otsuka Enter into Exclusive License Agreement to Develop and Market Eye Drug
08:41

Schedules & Filings

Schedules
Filings
Nov10
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 90 K, Net Income -56.88 M, EPS -1.0133

Aug11
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 15 K, Net Income -54.66 M, EPS -0.9773

May8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 14 K, Net Income -47.97 M, EPS -0.8605

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
CDTX
217.745
+105.44%
+111.755
CYPH
3.139
+78.34%
+1.371
IVVD
2.676
+51.16%
+0.900
BCG
2.005
+40.70%
+0.585
TRAW
2.490
+40.68%
+0.720
WTO
0.0278
+39.00%
+0.008
TOI
4.085
+32.63%
+1.005
BCAB
0.8690
+31.73%
+0.209
PGEN
5.011
+29.83%
+1.151
SMTK
1.866
+29.60%
+0.426
View More
Terms & Conditions
  • Terms of Service
  • Privacy Policy